Skip to main navigation
  • IR Home
  • News
  • Events & Presentations
  • Governance
    • Our Team
    • Board of Directors
    • Committee Composition
    • Documents & Charters
  • Financials
    • SEC Filings
  • Stock Info
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

News Releases

Oct 03, 2023
Rallybio to Present at the JonesTrading 2023 Healthcare Summit
Sep 03, 2023
Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Aug 31, 2023
Rallybio to Present at Upcoming Investor Conferences in September
Aug 08, 2023
Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates
Aug 02, 2023
Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference
Jul 11, 2023
Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW)
Jun 29, 2023
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023
Jun 24, 2023
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
Jun 09, 2023
Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis
Jun 01, 2023
Rallybio to Present at the Jefferies Healthcare Conference

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 20

Investor Tools

Unimagined therapies. Undreamed outcomes.

Rallybio Newsroom
Linkedin Twitter

info@rallybio.com

234 Church Street
Suite 1020
New Haven, CT 06510

+1 203-859-3820
+1 475-47-RALLY (72559)

© 2023 Rallybio | Terms of Use | Privacy Policy | Community Guidelines